MorphoSys Chooses Incyte As Its Global Tafasitamab Partner

Analysts Cheer MorphoSys’s Choice Of Commercial Ally And Deal’s Terms

 
• By Sten Stovall
Partnership
Duo Will Jointly Develop MorphoSys’s CD19 Targeting Antibody • Source: Shutterstock

More from Business

More from Scrip